Dyadic Announces Second Quarter 2020 Results and Highlights Recent Company Progress
Entered into two new collaborations with top tier animal health companies Entered into a fully funded human health collaboration with a top five global pharmaceutical company Started an animal trial for SARS-CoV-2 RBD vaccine candidate in Israel and another animal trial in European is expected to begin soon Dyadic selected by Frederick National Laboratory to engineer several C1 cell lines to express COVID-19 vaccine candidates Entered into a new...
Read more









